B · Normal
[Baili Tianheng: The first subject has been enrolled in the Phase III clinical trial of Yizekang] On September 9, Bailey Tianheng (688506.SH) announced that the company's independently developed world's first dual-antibody ADC Yizekang has completed the enrollment of the first subject in its Phase III clinical trial for the maintenance treatment of unresectable EGFR-mutated non-small cell lung cancer after concurrent radiotherapy and chemotherapy. Up to now, Yizekang has conducted more than 45 clinical trials in China and the United States, including 20 phase III clinical studies. Seven indications have been included in the list of breakthrough therapies by CDE, and two indications have been approved for marketing by NMPA.
Comments